{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T15:35:31Z","timestamp":1784475331731,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40119-021-00252-4","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T18:02:36Z","timestamp":1643479356000},"page":"113-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril\/Valsartan or Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"11","author":[{"given":"Emma","family":"Houchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Loefroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Schlienger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Corda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibasish","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvesh K.","family":"Satwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Studer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"8","key":"252_CR1","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254\u2013743.","journal-title":"Circulation"},{"key":"252_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21037\/amj.2020.03.03","volume":"5","author":"G Lippi","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15.","journal-title":"AME Med J"},{"issue":"10","key":"252_CR3","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ejhf.1531","volume":"21","author":"PM Seferovic","year":"2019","unstructured":"Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(10):1169\u201386.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"252_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Cardiac Fail. 2017;23(8):628\u201351.","journal-title":"J Cardiac Fail"},{"issue":"6","key":"252_CR5","first-page":"330","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L. Entresto (sacubitril\/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am Health Drug Benefits. 2015;8(6):330\u20134.","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"252_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"TM Maddox","year":"2021","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, et al. Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772\u2013810.","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"252_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"19","key":"252_CR8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","volume":"139","author":"DA Morrow","year":"2019","unstructured":"Morrow DA, Velazquez EJ, DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial. Circulation. 2019;139(19):2285\u20138.","journal-title":"Circulation"},{"issue":"6","key":"252_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539\u201348.","journal-title":"N Engl J Med"},{"issue":"9","key":"252_CR10","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jacc.2020.06.073","volume":"76","author":"AP Ambrosy","year":"2020","unstructured":"Ambrosy AP, Braunwald E, Morrow DA, et al. Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin\u2013angiotensin system antagonists. J Am Coll Cardiol. 2020;76(9):1034\u201348.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"252_CR11","doi-asserted-by":"publisher","first-page":"e011089","DOI":"10.1161\/JAHA.118.011089","volume":"8","author":"NM Albert","year":"2019","unstructured":"Albert NM, Swindle JP, Buysman EK, Chang C. Lower hospitalization and healthcare costs with sacubitril\/valsartan versus angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker in a retrospective analysis of patients with heart failure. J Am Heart Assoc. 2019;8(9):e011089.","journal-title":"J Am Heart Assoc"},{"key":"252_CR12","first-page":"A216","volume":"11","author":"C Chang","year":"2018","unstructured":"Chang C, Song X, Nguyen A, Smith D, Choi M, Duffy C. Hospitalizations of patients with heart failure and reduced ejection fraction treated with sacubitril\/valsartan (S\/V) vs. angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI\/ARB). Circ Cardiovas Qual Outcomes. 2018;11:A216.","journal-title":"Circ Cardiovas Qual Outcomes."},{"issue":"4","key":"252_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","volume":"74","author":"HY Chang","year":"2019","unstructured":"Chang HY, Feng AN, Fong MC, et al. Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real-world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74(4):372\u201380.","journal-title":"J Cardiol"},{"issue":"11","key":"252_CR14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.cardfail.2019.11.003","volume":"25","author":"SJ Greene","year":"2019","unstructured":"Greene SJ, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, Chang CL, Hammill BG, Luo N, Samsky MD, Heidenreich PA, Laskey WK, Yancy CW, Peterson PN, Curtis LH, Hernandez AF, Fonarow GC, O\u2019Brien EC. Clinical effectiveness of sacubitril\/valsartan among patients hospitalized for heart failure with reduced ejection fraction. J Cardiac Fail. 2019;25(11):937.","journal-title":"J Cardiac Fail"},{"issue":"11","key":"252_CR15","doi-asserted-by":"publisher","first-page":"e005691","DOI":"10.1161\/CIRCHEARTFAILURE.118.005691","volume":"12","author":"AF Mohanty","year":"2019","unstructured":"Mohanty AF, Levitan EB, Dodson JA, et al. Characteristics and healthcare utilization among veterans treated for heart failure with reduced ejection fraction who switched to sacubitril\/valsartan. Circ Heart Fail. 2019;12(11):e005691.","journal-title":"Circ Heart Fail"},{"key":"252_CR16","first-page":"A15928","volume":"138","author":"L Parlett","year":"2018","unstructured":"Parlett L, Gordan A, Sylvestrzak M, White J, Power T, Barron J. Hospitalization rates and costs among real-world users of sacubitril\/valsartan versus other heart failure medications. Circulation. 2018;138:A15928.","journal-title":"Circulation"},{"issue":"1","key":"252_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jchf.2019.08.003","volume":"8","author":"NY Tan","year":"2020","unstructured":"Tan NY, Sangaralingham LR, Sangaralingham SJ, et al. Comparative effectiveness of sacubitril-valsartan versus ACE\/ARB therapy in heart failure with reduced ejection fraction. JACC Heart Fail. 2020;8(1):43\u201354.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"252_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J, et al. Association of change in N-terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322(11):1\u201311.","journal-title":"JAMA"},{"issue":"5","key":"252_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.1465","volume":"21","author":"R Wachter","year":"2019","unstructured":"Wachter R, Fonseca AF, Balas B, et al. Real-world treatment patterns of sacubitril\/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail. 2019;21(5):588\u201397.","journal-title":"Eur J Heart Fail"},{"key":"252_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","volume":"331","author":"C Proudfoot","year":"2021","unstructured":"Proudfoot C, Studer R, Rajput T, et al. Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review. Int J Cardiol. 2021;331:164\u201371.","journal-title":"Int J Cardiol."},{"issue":"5","key":"252_CR21","doi-asserted-by":"publisher","first-page":"e006483","DOI":"10.1161\/CIRCOUTCOMES.120.006483","volume":"13","author":"K Joynt Maddox","year":"2020","unstructured":"Joynt Maddox K, Bleser WK, Crook HL, et al. Advancing value-based models for heart failure: a call to action from the value in healthcare initiative\u2019s value-based models learning collaborative. Circ Cardiovasc Qual Outcomes. 2020;13(5):e006483.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"252_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/RMHP.S130341","volume":"10","author":"MPH Kilgore","year":"2017","unstructured":"Kilgore MPH, Kielhorn A, Maya JF, Sharma P. Economic burden of hospitalizations of Medicare beneficiaries with heart failure. Risk Manag Healthc Policy. 2017;10:63\u201370.","journal-title":"Risk Manag Healthc Policy"},{"issue":"11","key":"252_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40273-020-00952-0","volume":"38","author":"M Urbich","year":"2020","unstructured":"Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014\u20132020). Pharmacoeconomics. 2020;38(11):1219\u201336.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"252_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1161\/CIRCOUTCOMES.110.957225","volume":"4","author":"SM Dunlay","year":"2011","unstructured":"Dunlay SM, Shah ND, Shi Q, et al. Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes. 2011;4(1):68\u201375.","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-021-00252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-021-00252-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-021-00252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T03:30:52Z","timestamp":1647660652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-021-00252-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["252"],"URL":"https:\/\/doi.org\/10.1007\/s40119-021-00252-4","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"17 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}